Cardiovascular

The FDA has signed off Cardiol Therapeutics Inc's (NASDAQ: CRDL) Investigational New Drug (IND) application for CardiolRx. Cardiol will commence a Phase 2, multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and tolerability of CardiolRx in...

Amarin Corp. (NASDAQ: AMRN) shares surged Monday after the company reported positive cardiovascular trial results for its fish oil capsules.   The Analyst H.C. Wainwright & Co. analyst Andrew S. Fein reiterated a Buy rating on Amarin and raised the price target from $10 to $...

Is Amarin's (NASDAQ: AMRN) Vascepa the victim of its own ineptitude, or the target of an effort by Big Pharma to keep it off the market? Those questions and others have been lobbed around lately by a variety of industry observers and investors, regarding Amarin's sole product, Vascepa – a...